# Ring Energy, Inc.: financial statements, quarterly

REI · NYSE · CIK 1384195 · [Energy](/sectors/energy.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rei.md) · [Financials](/companies/rei/financials.md) · [Filings](/companies/rei/filings.md) · [Insiders](/companies/rei/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rei/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [93.7](/filings/0001628280-24-045791.md) | [99.9 d](/filings/0001384195-26-000050.md) | [94.5](/filings/0001628280-25-023254.md) | [99.1](/filings/0001628280-25-038401.md) | [89.2](/filings/0001384195-25-000018.md) | [83.4 d](/filings/0001384195-26-000050.md) | [79.1](/filings/0001384195-26-000072.md) | [82.6](/filings/0001384195-26-000080.md) | [78.6](/filings/0001384195-25-000018.md) | [66.9 d](/filings/0001384195-26-000050.md) | [73.7](/filings/0001384195-26-000072.md) | [105](/filings/0001384195-26-000080.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [39.6](/filings/0001628280-24-045791.md) | [40.9 d](/filings/0001384195-26-000050.md) | [37.6](/filings/0001628280-25-023254.md) | [41.8](/filings/0001628280-25-038401.md) | [29.8](/filings/0001384195-25-000018.md) | [23.6 d](/filings/0001384195-26-000050.md) | [22.4](/filings/0001384195-26-000072.md) | [23.5](/filings/0001384195-26-000080.md) | [(55.0)](/filings/0001384195-25-000018.md) | [(25.2) d](/filings/0001384195-26-000050.md) | [(142)](/filings/0001384195-26-000072.md) | [50.3](/filings/0001384195-26-000080.md) |
| Interest expense | $m | [11.4](/filings/0001628280-23-036452.md) | [11.6 d](/filings/0001628280-24-009691.md) | [11.5](/filings/0001628280-24-020695.md) | [10.9](/filings/0001628280-25-038401.md) | [10.8](/filings/0001384195-25-000018.md) | [10.1 d](/filings/0001384195-26-000050.md) | [9.5](/filings/0001384195-26-000072.md) | [11.8](/filings/0001384195-26-000080.md) | [10.1](/filings/0001384195-25-000018.md) | [9.1 d](/filings/0001384195-26-000050.md) | [8.6](/filings/0001384195-26-000072.md) | [8.4](/filings/0001384195-26-000080.md) |
| Income tax | $m | [(3.4)](/filings/0001628280-24-045791.md) | [7.9 d](/filings/0001384195-26-000050.md) | [1.7](/filings/0001628280-25-023254.md) | [6.8](/filings/0001628280-25-038401.md) | [10.1](/filings/0001384195-25-000018.md) | [1.8 d](/filings/0001384195-26-000050.md) | [3.0](/filings/0001384195-26-000072.md) | [6.1](/filings/0001384195-26-000080.md) | [(12.8)](/filings/0001384195-25-000018.md) | [(3.8) d](/filings/0001384195-26-000050.md) | [(12.0)](/filings/0001384195-26-000072.md) | [1.1](/filings/0001384195-26-000080.md) |
| Net income | $m | [(7.5)](/filings/0001628280-24-045791.md) | [50.9 d](/filings/0001384195-26-000050.md) | [5.5](/filings/0001384195-25-000018.md) | [22.4](/filings/0001384195-25-000018.md) | [33.9](/filings/0001384195-25-000018.md) | [5.7 d](/filings/0001384195-26-000050.md) | [9.1](/filings/0001384195-26-000080.md) | [20.6](/filings/0001384195-26-000080.md) | [(51.6)](/filings/0001384195-25-000018.md) | [(12.8) d](/filings/0001384195-26-000050.md) | [(221)](/filings/0001384195-26-000080.md) | [64.8](/filings/0001384195-26-000080.md) |
| Diluted EPS | $ per share | [(0.04)](/filings/0001628280-24-045791.md) | not reported | [0.03](/filings/0001628280-25-023254.md) | [0.11](/filings/0001628280-25-038401.md) | [0.17](/filings/0001384195-25-000018.md) | not reported | [0.05](/filings/0001384195-26-000072.md) | [0.10](/filings/0001384195-26-000080.md) | [(0.25)](/filings/0001384195-25-000018.md) | not reported | [(1.06)](/filings/0001384195-26-000072.md) | [0.27](/filings/0001384195-26-000080.md) |
| Basic EPS | $ per share | [(0.04)](/filings/0001628280-24-045791.md) | not reported | [0.03](/filings/0001628280-25-023254.md) | [0.11](/filings/0001628280-25-038401.md) | [0.17](/filings/0001384195-25-000018.md) | not reported | [0.05](/filings/0001384195-26-000072.md) | [0.10](/filings/0001384195-26-000080.md) | [(0.25)](/filings/0001384195-25-000018.md) | not reported | [(1.06)](/filings/0001384195-26-000072.md) | [0.28](/filings/0001384195-26-000080.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.1](/filings/0001628280-23-036452.md) | [0.3](/filings/0001628280-25-010585.md) | [1.4](/filings/0001628280-24-020695.md) | [1.2](/filings/0001628280-24-035242.md) | [0.0](/filings/0001628280-24-045791.md) | [1.9](/filings/0001384195-26-000050.md) | [1.1](/filings/0001628280-25-023254.md) | [0.0](/filings/0001628280-25-038401.md) | [0.3](/filings/0001384195-25-000018.md) | [0.9](/filings/0001384195-26-000080.md) | [1.0](/filings/0001384195-26-000072.md) | [1.1](/filings/0001384195-26-000080.md) |
| Current assets | $m | [58.6](/filings/0001628280-23-036452.md) | [55.9](/filings/0001628280-25-010585.md) | [58.7](/filings/0001628280-24-020695.md) | [56.2](/filings/0001628280-24-035242.md) | [52.8](/filings/0001628280-24-045791.md) | [50.4](/filings/0001384195-26-000050.md) | [48.7](/filings/0001628280-25-023254.md) | [62.4](/filings/0001628280-25-038401.md) | [55.8](/filings/0001384195-25-000018.md) | [62.1](/filings/0001384195-26-000080.md) | [59.3](/filings/0001384195-26-000072.md) | [60.8](/filings/0001384195-26-000080.md) |
| Total assets | $m | [1,363](/filings/0001628280-23-036452.md) | [1,376](/filings/0001384195-26-000050.md) | [1,385](/filings/0001628280-25-023254.md) | [1,390](/filings/0001628280-25-038401.md) | [1,400](/filings/0001384195-25-000018.md) | [1,408](/filings/0001384195-26-000050.md) | [1,506](/filings/0001384195-26-000072.md) | [1,516](/filings/0001384195-26-000080.md) | [1,435](/filings/0001384195-25-000018.md) | [1,412](/filings/0001384195-26-000080.md) | [1,255](/filings/0001384195-26-000072.md) | [1,282](/filings/0001384195-26-000080.md) |
| Current liabilities | $m | [152](/filings/0001628280-23-036452.md) | [114](/filings/0001628280-25-010585.md) | [118](/filings/0001628280-24-020695.md) | [111](/filings/0001628280-24-035242.md) | [97.6](/filings/0001628280-24-045791.md) | [105](/filings/0001384195-26-000050.md) | [104](/filings/0001628280-25-023254.md) | [98.3](/filings/0001628280-25-038401.md) | [102](/filings/0001384195-25-000018.md) | [93.7](/filings/0001384195-26-000080.md) | [148](/filings/0001384195-26-000072.md) | [113](/filings/0001384195-26-000080.md) |
| Total liabilities | $m | [630](/filings/0001628280-23-036452.md) | [590](/filings/0001628280-25-010585.md) | [592](/filings/0001628280-24-020695.md) | [572](/filings/0001628280-24-035242.md) | [548](/filings/0001628280-24-045791.md) | [549](/filings/0001384195-26-000050.md) | [630](/filings/0001628280-25-023254.md) | [618](/filings/0001628280-25-038401.md) | [587](/filings/0001384195-25-000018.md) | [570](/filings/0001384195-26-000080.md) | [633](/filings/0001384195-26-000072.md) | [528](/filings/0001384195-26-000080.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [733](/filings/0001628280-24-045791.md) | [787](/filings/0001384195-26-000050.md) | [793](/filings/0001384195-25-000018.md) | [817](/filings/0001384195-25-000018.md) | [851](/filings/0001384195-25-000018.md) | [864](/filings/0001384195-26-000080.md) | [882](/filings/0001384195-26-000080.md) | [904](/filings/0001384195-26-000080.md) | [848](/filings/0001384195-25-000018.md) | [842](/filings/0001384195-26-000080.md) | [622](/filings/0001384195-26-000080.md) | [753](/filings/0001384195-26-000080.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [55.4 d](/filings/0001628280-24-045791.md) | [55.7 d](/filings/0001384195-26-000050.md) | [45.2](/filings/0001628280-25-023254.md) | [50.6 d](/filings/0001628280-25-038401.md) | [51.3 d](/filings/0001384195-25-000018.md) | [47.3 d](/filings/0001384195-26-000050.md) | [28.4](/filings/0001384195-26-000072.md) | [33.3 d](/filings/0001384195-26-000080.md) | [44.5 d](/filings/0001384195-25-000018.md) | [44.7 d](/filings/0001384195-26-000050.md) | [25.9](/filings/0001384195-26-000072.md) | [40.8 d](/filings/0001384195-26-000080.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q4 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [152](/filings/0001628280-23-036452.md) | [190](/filings/0001628280-24-020695.md) | [196](/filings/0001628280-24-035242.md) | [195](/filings/0001628280-24-045791.md) | [199](/filings/0001628280-25-023254.md) | [200](/filings/0001628280-25-038401.md) | [201](/filings/0001384195-25-000018.md) | [201](/filings/0001384195-26-000072.md) | [207](/filings/0001384195-26-000080.md) | [207](/filings/0001384195-25-000018.md) | [209](/filings/0001384195-26-000072.md) | [238](/filings/0001384195-26-000080.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 260,539,607 at 2026-08-05, from the cover of the [10-Q filed 2026-08-05](/filings/0001384195-26-000080.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.